Originally investigated for its potential to combat obesity, metabolic syndrome, and age-related decline, this NNMT (nicotinamide N-methyltransferase) inhibitor has shown promise in boosting fat metabolism, preserving lean muscle mass, and increasing energy efficiency
Clinical Study Results (TRIUMPH & TRANSCEND) Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors: Weight reduction: In phase 2 and phase 3 clinical studies, treated participants achieved approximately 24% to 28.7% weight loss over 4868 weeks
Personalized guidance to build lasting habits, support your metabolism, and make the most of your medication
using an MSD kit (U-PLEX Custom Metabolic Group 1 Assays, K152ACM-1, MSD, Rockville, MD))
The compounds don't affect gastric motility or satiety signaling
We will notify You of any changes by posting the new Privacy Policy on this page